SPHRY

Starpharma Holdings Ltd.

 
Sponsored ADR (1 ADS : 10 Ordinary) International Reporting
OTCQX International OTCQX Advisor: BNY Mellon
Verified Company Profile 6/30/2017
Contact Info
  • 4-6 Southampton Crescent
  • Abbotsford, VIC 3067
  • Australia

Business Description


 
Financial Reporting/Disclosure
Reporting Status International Reporting: ASX - Australian Securities Exchange
Audited Financials Audited
Latest Report Sep 30, 2017 Quarterly Report
CIK 0001308380
Fiscal Year End 6/30
OTC Marketplace OTCQX International
Profile Data
SIC - Industry Classification 8731 - Commercial physical research
Incorporated In: Australia
Year of Inc. 1997
Employees 40 a/o Jul 01, 2011
Company Officers/Contacts
Dr. Jackie Fairley CEO, IR, Managing Director
Nigel Baade CFO, Secretary
Company Directors
Robert Thomas Chairman
Richard Hazleton
Zita Peach
Peter Turvey
Company Notes
  • Sponsored for OTCQX by BNY Mellon on 3/26/2007.
  • Formerly=Starpharma Pooled Development Ltd. until 4-04
Service Providers
OTCQX Advisor
BNY Mellon
101 Barclay Street
22nd Floor
New York, NY, 10286
USA

Accounting/Auditing Firm
PricewaterhouseCoopers LLP
Level 19 Freshwater Place
2 Southbank Boulevard
Southbank, VIC, 3006
Australia

Legal Counsel
Not Available
Investor Relations Firm
Not Available
SPHRY Security Details Other Company Securities
Share Structure
Market Value1 $396,035,343 a/o Nov 20, 2017
Authorized Shares Unlimited a/o Jun 13, 2017
Outstanding Shares 369,091,652 a/o Jun 13, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value No Par Value
Transfer Agent(s)
BNY Mellon
Shareholders
Shareholders of Record 4,956 a/o Jul 31, 2016
Non US Stock Exchange Listing
SPL - ASX - Australian Securities Exchange - Qualified
Short Selling Data
Short Interest 2,927 (4.09%)
Oct 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security